Francesco G. Salituro

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

Dimitrios Anastasiou, Yimin Yu, William J. Israelsen et al. · Nature Chemical Biology · 2012 · 804 citations · Full text

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Jeremy Travins, Byron DeLaBarre et al. · Science · 2013 · 789 citations

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations

Katharine Yen, Jeremy Travins, Fang Wang et al. · Cancer Discovery · 2017 · 444 citations · Full text

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Janeta Popovici-Müller, René M. Lemieux, Erin Artin et al. · ACS Medicinal Chemistry Letters · 2018 · 422 citations · Full text

Idh1 Mutant Cancers, Somatic Point Mutations, Somatic Variant +14

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

Michael P. Clark, Mark W. Ledeboer, Ioana Davies et al. · Journal of Medicinal Chemistry · 2014 · 207 citations · Full text

Influenza Pb2, Medicinal Chemistry, Medicine +13